Latest News about BIIB
Recent news which mentions BIIB
What More Can Support Biogen/Sage's Zuranolone Resubmission: Analysts See Uncertain Road Ahead
August 07, 2023
From Benzinga
FDA's Rejection of Sage/Biogen's Zuranolone Boosts Prospects for Axsome's Auvelity, Analyst Says
August 07, 2023
From Benzinga
Sage Therapeutics’ stock drops 49% after FDA approves zuranolone for postpartum depression but not for major depressive disorder
August 07, 2023
From MarketWatch
From Benzinga
FDA Approves Sage Therapeutics/Biogen's Zuranolone For One Type Of Depression, Rejects For Another
August 07, 2023
From Benzinga
From MarketWatch
3 ‘Strong Buy’ Biotech Stocks You Should Be Loading Up On Now
August 02, 2023
From InvestorPlace
From InvestorPlace
From Motley Fool
Quest Diagnostics launches first at-home blood test to assess risk of developing Alzheimer’s disease
July 31, 2023
From MarketWatch
From Benzinga
Better Alzheimer's Drug Stock: Eli Lilly vs. Biogen
July 31, 2023
From Motley Fool
Could This Stock Be the Next Biotech Buyout?
July 31, 2023
From Motley Fool
From InvestorPlace
From InvestorPlace
Reata's Acquisition Fits Biogen's Strategy Despite High Cost: Analyst Says High Level Regulatory Scrutiny Not Anticipated
July 28, 2023
From Benzinga
From Benzinga
From MarketWatch
Why Is Reata Pharmaceuticals (RETA) Stock Up 53% Today?
July 28, 2023
From InvestorPlace
Biogen Bolsters Rare Disease Portfolio, Agrees To Buy Reata Pharmaceuticals With Enterprise Value Of $7.3B
July 28, 2023
From Benzinga
Biogen agrees to acquire Reata Pharmaceuticals for $7.3 billion to boost its rare-disease offering
July 28, 2023
From MarketWatch
From Benzinga
Tickers
BIIB
From Motley Fool
Why Sage Therapeutics Stock Is Tumbling Today
July 26, 2023
From Motley Fool
From MarketWatch
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
